Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited

Medicine Research ›› 2020, Vol. 4 ›› Issue (3): 200011-.DOI: 10.21127/yaoyimr20200011

Special Issue: Anticancer Agents

• Minireviews • Previous Articles     Next Articles

Recent Advances on Small-Molecule Epidermal Growth Factor Receptor Inhibitors

Bo-Ya Shi,a Ze-Hao Wang,a Xuan-Jun Wang,a,b Jun Sheng,*,a and Cheng-Ting Zi*,a,b   

  1. a Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, Yunnan 650201, China
    b College of Science, Yunnan Agricultural University, Kunming, Yunnan 650201, China
  • Received:2020-06-05 Revised:2020-07-19 Online:2020-09-22 Published:2020-09-22
  • Contact: Email: shengj@ynau.edu.cn (J. S.), zichengting@126.com (C. Z.)
  • Supported by:

Abstract: The epidermal growth factor receptor (EGFR) is a kind of cell membrane surface receptor with tyrosine kinase activity, which is closely related to the growth, proliferation, differentiation, apoptosis, metastasis and other processes of tumor cells. Targeting EGFR tyrosine kinase inhibitors has become a hot topic for drug development for treatment of non-small-cell cancer (NSCLC). Herein, we summarized recent advances on the targeted therapeutic drugs for NSCLC in recent years.


Key words: non-small cell lung cancer, epidermal growth factor receptor, inhibitors

Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States